Skip to content

Global Myofascial Treatment With Shockwave for Non-Specific Low Back Pain

Global Myofascial Treatment With Focused Shockwave for Non-Specific Low Back Pain: a Randomized Control Trial.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07692347
Enrollment
44
Registered
2026-07-09
Start date
2022-08-01
Completion date
2026-04-15
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Keywords

low back pain, chronic low back pain, shockwave

Brief summary

This study aims to examine the effects of shockwave therapy on myofascial tissue (muscles, fascia, and connective tissue), focusing on pain reduction and improvement of mobility. The results will be compared with those of conventional manual physiotherapy. Myofascial tissue can be a source of back pain, as it may contain painful spots known as myofascial trigger points (MTrPs). Shockwave therapy can stimulate these trigger points, potentially leading to muscle and fascia relaxation and, as a result, a decrease in pain. The study investigates how focused shockwave trigger point therapy influences back function and pain perception compared to traditional physiotherapeutic treatment. Participation is voluntary. The examinations will only be carried out if you provide written informed consent. You may refuse participation or withdraw your consent at any time without any disadvantages.

Interventions

DEVICEShockwave therapy

Shockwave therapy can stimulate these trigger points, potentially leading to muscle and fascia relaxation and, as a result, a decrease in pain.

PROCEDUREConventional physiotherapy

Conventional physiotherapy to treat low back pain

Sponsors

University Hospital Muenster
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Chronic low back pain (LBP) of the lumbar spine lasting more than 12 weeks * age between 18 and 70 years * pain stage 1 or 2 according to Gerbershagen * female, male or diverse * capable of giving informed consent

Exclusion criteria

* Severe neurological * vascular * neoplastic or bony disorders, as well as cognitive impairments * according to the judgment and assessment of the examiner * flexisting radicular symptoms (e.g., foot drop).

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Scale for Pain3 monthsPain intensity measured using the Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate worse pain.
Oswestry Disability Index3 monthsDisability related to low back pain measured using the Oswestry Disability Index (ODI). Scores range from 0 to 100, where higher scores indicate greater disability and worse functional outcome.

Secondary

MeasureTime frameDescription
Quebec Back Pain Disability Scale3 MonthsFunctional disability measured using the Quebec Back Pain Disability Scale (QBPDS). Scores range from 0 to 100, where higher scores indicate greater disability and a worse outcome.
SF-12 Health Survey3 monthsHealth-related quality of life measured using the 12-Item Short Form Health Survey (SF-12). Scores range from 0 to 100 for the Physical Component Summary (PCS) and Mental Component Summary (MCS), where higher scores indicate better health-related quality of life and a better outcome.
Roland-Morris Disability Questionnaire (RMDQ)3 monthsPhysical disability measured using the Roland-Morris Disability Questionnaire (RMDQ). Scores range from 0 to 24, with higher scores indicating greater disability and a worse outcome.

Countries

Germany

Contacts

STUDY_DIRECTORRichard Stange, Prof.

Institut für Muskuloskelettale Medizin (IMM) Abteilung für Muskuloskelettale Regenerative Medizin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026